DocWire News Editors

DocwireNews

In the&nbsp;pathophysiology of psoriasis, tyrosine kinase 2 (TYK2) signaling pathways&nbsp;are connected; some TYK2 signaling pathways might be&nbsp;effective in treating psoriasis.&nbsp;In a study published in&nbsp;The New England Journal of Medicine, researchers aim to assess how selective&nbsp;TYK2&nbsp;inhibition&nbsp;affects psoriasis.&nbsp;In the&nbsp;phase 2, double-blind trial,&nbsp;the&nbsp;TYK2 inhibitor&nbsp;BMS-986165&nbsp;was given to&nbsp;adults with moderate-to-severe psoriasis, excluding patients with a previous lack of response to agents targeting cytokine signaling through the same tyrosine kinase pathway.&nbsp;Patients&nbsp;(n=267)&nbsp;were randomly assigned to receive&nbsp;3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily,&nbsp;or to receive placebo.&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
The next in the JAK family to emerge in trials from <a href="https://twitter.com/NEJM?ref_src=twsrc%5Etfw">@NEJM</a> &ndash; Tyk2 inhibition in psoriasis: <a href="https://t.co/e7kusOCfL5">https://t.co/e7kusOCfL5</a>
&mdash; Rheumatology &amp; Rheumatology Advances in Practice (@RheumJnl) <a href="https://twitter.com/RheumJnl/status/1039913392885170177?ref_src=twsrc%5Etfw">September 12, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Original Article: Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis <a href="https://t.co/IWJJa9EpeU">https://t.co/IWJJa9EpeU</a> <a href="https://twitter.com/hashtag/EADV2018?src=hash&amp;ref_src=twsrc%5Etfw">#EADV2018</a> <a href="https://t.co/l67kjKViig">pic.twitter.com/l67kjKViig</a>
&mdash; NEJM (@NEJM) <a href="https://twitter.com/NEJM/status/1039756773719269379?ref_src=twsrc%5Etfw">September 12, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The&nbsp;percentage of patients&nbsp;at week 12&nbsp;with a 75% or greater reduction in the PASI score was 7% (3 of 45 patients) with placebo, 9% (4 of 44 patients) with 3 mg of BMS-986165 every other day (P=0.49 vs. placebo), 39% (17 of 44 patients) with 3 mg daily (P&lt;0.001 vs. placebo), 69% (31 of 45 patients) with 3 mg twice daily (P&lt;0.001 vs. placebo), 67% (30 of 45 patients) with 6 mg twice daily (P&lt;0.001 vs. placebo), and 75% (33 of 44 patients) with 12 mg daily (P&lt;0.001 vs. placebo)&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <a href="https://t.co/uUseR0kuo3">https://t.co/uUseR0kuo3</a>
&mdash; MelanomaResearchPapers (@MelanRes_papers) <a href="https://twitter.com/MelanRes_papers/status/1040231256682770432?ref_src=twsrc%5Etfw">September 13, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Results showed that&nbsp;&ldquo;selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than did placebo over a period of 12 weeks&rdquo; but that more research needed to be completed to determine its safety and durability of effect in patients with psoriasis.&nbsp;Check out&nbsp;an article on&nbsp;the relation of&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/gout-hearing-impairment-elderly/">gout and hearing impairment in the elderly</a>.&nbsp;SOURCE:<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1806382">&nbsp;</a>NEJM&nbsp;

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

TYK2 Signaling Pathways for Psoriasis

Psoriasis

In the pathophysiology of psoriasis, tyrosine kinase 2 (TYK2) signaling pathways are connected; some TYK2 signaling pathways might be effective in treating psoriasis. In a ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe